ArticleInfection2026
Longer vs. shorter all-oral bedaquiline-based regimens for drug-resistant tuberculosis: real-world evidence from a high-burden setting.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organization recommends all-oral bedaquiline-based regimens for drug-resistant tuberculosis (DR-TB), including a longer M/XDR-TB regimen (18-20 months) and a shorter RR/MDR-TB regimen (9-11 months). Comparative effectiveness data under routine programmatic conditions remain limited.
objectiveTo compare clinical and microbiological outcomes of longer versus shorter all-oral treatment regimens.
methodsWe conducted a prospective observational cohort study between January and December 2022. Patients with pulmonary or extrapulmonary RR/MDR-TB were enrolled and treated according to national programmatic guidelines. Six-month culture conversion and end-of-treatment clinical outcomes were compared between longer and shorter all-oral bedaquiline-based regimens using multivariable logistic regression adjusted for pre-specified confounders.
resultsOf 1427 patients screened, 894 (62.6%) were included; 691 (77.3%) received the longer regimen and 203 (22.7%) the shorter regimen. Baseline demographic and clinical characteristics were broadly comparable, although resistance profiles differed because regimen allocation was guided by drug susceptibility testing and programmatic eligibility criteria. Six-month culture results were available for 778 (87.0%) patients; 96 (10.7%) died and 20 (2.3%) were lost to follow-up. Culture conversion was significantly higher with the longer regimen than the shorter regimen (579/596, 97.1% vs. 146/182, 80.2%; p < 0.001). In intention-to-treat analysis, favorable outcomes occurred in 525/691 (76.0%) patients receiving the longer regimen and 135/203 (66.5%) receiving the shorter regimen (p = 0.006). The longer regimen was independently associated with favorable outcomes (adjusted odds ratio 1.58, 95% CI 1.15-2.17; p = 0.004).
conclusionsBaseline demographic and clinical characteristics were broadly comparable, although resistance profiles differed because regimen allocation was guided by drug susceptibility testing and programmatic eligibility criteria.
Indexed as
Identifiers
42455264What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.